The global autoimmune disease diagnostics market is expected to reach a value of USD 5.0 billion by 2025, based on a new report by Grand View Research, Inc. Government organizations along with related associations strive to curb such high healthcare costs and simultaneously provide improved diagnostic and therapeutic solutions to the patients. This has resulted in increased funding by the NIH for R&D programs related to autoimmune diseases.
Moreover,
the presence of favorable government initiatives aimed at curbing the incidence
of these diseases and developing viable diagnostic & treatment options is
expected to drive market growth over the forecast period.
Growing
volume of autoimmune diagnostic procedures has heightened the need for
instruments and facilities rendering faster and effective results. In an
attempt to cater to ever-increasing procedure volumes, diagnostic laboratories
are rapidly moving toward automation. Lab automation helps decrease workload
via rapid turnaround times and helps generate standardized & reproducible
results.
For Full Research Report On Autoimmune Disease Diagnostics Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/autoimmune-disease-diagnostics-industry
Further key
findings from the study suggest:
- Localized autoimmune disease
diagnostics was the largest segment in 2015 owing to high usage for type 1
diabetes and idiopathic thrombocytopenic purpura
- Type 1 diabetes is estimated
to grow at a significant growth rate of over 4.0% in the localized disease
type segment
- Systemic disease diagnostics
is anticipated to witness lucrative CAGR of around 5.0% over the forecast
period due to increasing R&D for the development of novel diagnostic
biomarkers for the treatment of rheumatoid arthritis and systemic lupus
erythematosus
- Rheumatoid arthritis is one
of the most recurring autoimmune disorders further demanding a high amount
of rapid diagnostics for exploring better alternative treatments
- North America was the
largest regional market in 2015. The high market penetration rate of
technologically advanced products and increased lab automation rate are
some of the factors contributing to its large share
- Asia Pacific region is
anticipated to grow at the fastest CAGR of above 4.0% over the forecast
period owing to increasing focus on type 1 diabetes diagnosis
- Some of the key players of
this market include F. Hoffmann-La Roche Ltd; Siemens Healthineers; Abbott
Laboratories; Beckman Coulter, Inc.; SQI Diagnostics; Quest Diagnostics;
EUROIMMUN AG; AESKU. Diagnostics; Inova Diagnostics, Inc.; Crescendo
Bioscience, Inc.; bioMerieux SA; Bio-Rad Laboratories, Inc.; and Hemagen
Diagnostics, Inc.
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/autoimmune-disease-diagnostics-industry/request/rs1
Grand View Research has segmented
the autoimmune disease diagnostics market by type and region:
Autoimmune Disease
Diagnostics Type Outlook (Revenue, USD Million, 2014 - 2025)
- Systemic autoimmune disease
diagnostics
- Rheumatoid arthritis
- Ankylosing spondylitis
- Systemic Lupus
Erythematosus (SLE)
- Others
- Localized autoimmune disease
diagnostics
- Multiple sclerosis
- Type 1 diabetes
- Hashimoto's Thyroiditis
- Idiopathic thrombocytopenic
purpura
- Others
Autoimmune Disease
Diagnostics Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- The U.S.
- Canada
- Europe
- Germany
- The U.K.
- Asia Pacific
- China
- Japan
- India
- Latin America
- Mexico
- Brazil
- MEA
- South Africa
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment